Top

Pituitary

Published in:

Open Access 01-02-2018

Association between FTO gene polymorphisms and HDL cholesterol concentration may cause higher risk of cardiovascular disease in patients with acromegaly

Authors: Aleksandra Franczak, Katarzyna Kolačkov, Aleksandra Jawiarczyk-Przybyłowska, Marek Bolanowski

Published in: Pituitary | Issue 1/2018

Abstract

Introduction

Cardiovascular diseases are main cause of morbidity and mortality in acromegaly. Polymorphisms of FTO gene are associated with obesity and increased risk of CVD (independently of BMI). Aim of this study was to investigate the allele frequencies of two FTO gene polymorphisms: rs9939609 and rs9930506 in patients with acromegaly and to examine the association of FTO gene polymorphisms with BMI and selected metabolic parameters.

Materials and methods

Identification of two single nucleotide polymorphisms of FTO gene was carried out in 51 patients with acromegaly using the minisequencing method.

Results

The risk-allele frequencies of rs9939609 and rs9930506 polymorphisms were 0.471 and 0.529, respectively and they were higher than in general European population. There is no association of FTO gene polymorphisms with BMI, glucose, total cholesterol, LDL cholesterol and triglyceride. The risk alleles were associated with decreased HDL cholesterol concentration. Homozygotes for the rs9939609-risk allele had 1.25-fold lower HDL cholesterol concentration than carriers of the TT genotype (p = 0.0024). The estimated average decrease in HDL cholesterol concentration per risk allele for rs9930506 was 11.2%. Nevertheless, statistically significant differences were observed only between AG versus GG and AA versus GG genotypes. Homozygotes for the rs9930506-risk allele had 1.27-fold lower HDL cholesterol concentration than carriers of the AA genotype (p = 0.007).

Conclusion

The risk-allele frequencies of studied polymorphisms in acromegaly were higher than in general European population. There is an association between FTO gene polymorphisms and HDL cholesterol concentration, suggesting FTO gene polymorphisms may be associated with higher CVD risk in patients with acromegaly.

Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–152CrossRefPubMed

Bolanowski M, Ruchała M, Zgliczyński W, Kos-Kudła B, Bałdys-Waligórska A, Zieliński G, Bednarczuk T, Hubalewska-Dydejczyk A, Kamiński G, Marek B, Daroszewski J, Waśko R, Lewiński A (2014) Acromegaly—a novel view of the patient. Polish proposals for diagnostic and therapeutic procedures in the light of recent reports. Endokrynol Pol 65:326–331CrossRefPubMed

Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89(2):667–674CrossRefPubMed

Manolio TA, Collins FS (2009) The HapMap and Genome-Wide Association Studies in diagnosis and therapy. Annu Rev Med 60:443–456CrossRefPubMedPubMedCentral

Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JR, Elliott KS, Lango H, Rayner NW, Shields B, Harries LW, Barrett JC, Ellard S, Groves CJ, Knight B, Patch AM, Ness AR, Ebrahim S, Lawlor DA, Ring SM, Ben-Shlomo Y, Jarvelin MR, Sovio U, Bennett AJ, Melzer D, Ferrucci L, Loos RJ, Barroso I, Wareham NJ, Karpe F, Owen KR, Cardon LR, Walker M, Hitman GA, Palmer CN, Doney AS, Morris AD, Smith GD, Hattersley AT, McCarthy MI (2007) A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316:889–894CrossRefPubMedPubMedCentral

Scuteri A, Sanna S, Chen WM, Uda M, Albai G, Strait J, Najjar S, Nagaraja R, Orru M, Usala G, Dei M, Lai S, Maschio A, Busonero F, Mulas A, Ehret GB, Fink AA, Weder AB, Cooper RS, Galan P, Chakravarti A, Schlessinger D, Cao A, Lakatta E, Abecasis GR (2007) Genome-Wide Association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet 3:1200–1210CrossRef

Doney A, Dannfald J, Kimber CH, Donnelly LA, Pearson E, Morris AD, Palmer CN (2009) The FTO gene is associated with an atherogenic lipid profile and myocardial infarction in patients with type 2 diabetes: a go-DARTS study. Circ Cardiovasc Genet 2:255–259CrossRefPubMedPubMedCentral

Lappalainen T, Kolehmainen M, Schwab US, Tolppanen AM, Stančáková A, Lindström J, Eriksson JG, Keinänen-Kiukaanniemi S, Aunola S, Ilanne-Parikka P, Herder C, Koenig W, Gylling H, Kolb H, Tuomilehto J, Kuusisto J, Uusitupa M (2011) Association of the FTO gene variant (rs9939609) with cardiovascular disease in men with abnormal glucose metabolism—The Finnish Diabetes Prevention Study. Nutr Metab Cardiovasc Dis 21:691–698CrossRefPubMed

Liu C, Mou S, Pan C (2013) The FTO gene rs9939609 polymorphism predicts risk of cardiovascular disease: a systematic review and meta-analysis. PLoS ONE 8:e71901CrossRefPubMedPubMedCentral

10.

Gerken T, Girard CA, Tung YC, Webby CJ, Saudek V, Hewitson KS, Yeo GS, McDonough MA, Cunliffe S, McNeill LA, Galvanovskis J, Rorsman P, Robins P, Prieur X, Coll AP, Ma M, Jovanovic Z, Farooqi IS, Sedgwick B, Barroso I, Lindahl T, Ponting CP, Ashcroft FM, O’Rahilly S, Schofield C (2007) The obesity-associated FTO gene encodes a 2-oxoglutarate–dependent nucleic acid demethylase. Science 318:1469–1472CrossRefPubMedPubMedCentral

11.

Jia G, Yang CG, Yang S, Jian X, Yi C, Zhou Z, He C (2008) Oxidative demethylation of 3-methylthymine and 3-methyluracil in single-stranded DNA and RNA by mouse and human FTO. FEBS Lett 15:23–24

12.

Rosskopf D, Schwahn C, Neumann F, Bornhorst A, Rimmbach C, Mischke M, Wolf S, Geissler I, Kocher T, Grabe HJ, Nauck M, Hebebrand J, Kroemer HK, Friedrich N, Völzke H, Wallaschofski H (2011) The growth hormone - IGF-I axis as a mediator for the association between FTO variants and body mass index: results of the Study of Health in Pomerania. Int J Obes 35:364–372CrossRef

13.

Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative centrifuge. Clin Chem 18:499–502PubMed

14.

Kolačkov K, Łaczmański Ł, Lwow F, Ramsey D, Zdrojowy-Wełna A, Tupikowska M, Bednarek-Tupikowska G (2016) The frequencies of haplotypes of FTO gene variants and their association with the distribution of body fat in non-obese Poles. Adv Clin Exp Med 25(1):33–42CrossRefPubMed

15.

Arking D, Chakravarti A (2009) Understanding cardiovascular disease through the lens of genome-wide assiociation studies. Cell Press 25(9):387–394

16.

Turgut S, Topsakal S, Ata MT, Herek D, Akın F, Özkan Ş, Turgut G (2016) Leptin receptor gene polymorphism may affect subclinical atherosclerosis in patients with acromegaly. Med Biotechnol 8(3):145–150

17.

Turgut S, Akın F, Ayada C, Topsakal S, Yerlikaya E, Turgut G (2012) The growth hormone receptor polymorphism in patients with acromegaly: relationship to BMI and glucose metabolism. Pituitary 15:374–379CrossRefPubMed

18.

Oguz E, Tabur S, Akbas H, Duzen IV, Karabag H, Akkafa F, Ozkaya M, Alasehirli B (2015) The association of ICAM E469K with cardiovascular characteristics of acromegaly. Eur Rev Med Pharmacol Sci 19:1673–1679PubMed

19.

International HapMap Project: ftp://ftp.ncbi.nlm.nih.gov/hapmap/. Accessed 12 May 2017

20.

Zdrojowy-Wełna A (2017) Fat mass and obesity related (FTO) gene polymorphism in Lower Silesia population, and its relation to selected factors of cardiovascular risk (doctoral thesis, in Polish), Wroclaw

21.

Freathy RM, Timpson NJ, Lawlor DA, Pouta A, Ben-Shlomo Y, Ruokonen A, Ebrahim S, Shields B, Zeggini E, Weedon MN, Lindgren CM, Lango H, Melzer D, Ferrucci L, Paolisso G, Neville MJ, Karpe F, Palmer CN, Morris AD, Elliott P, Jarvelin MR, Smith GD, McCarthy MI, Hattersley AT, Frayling TM (2008) Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes 57:1419–1426CrossRefPubMedPubMedCentral

22.

Circulation. Third Report of the National Cholesterol Education Program (NCEP) Exper Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III) Final Report. Internet: http://circ.ahajournals.org/content/106/25/3143.long. Accessed 20 July 2017

Title: Association between FTO gene polymorphisms and HDL cholesterol concentration may cause higher risk of cardiovascular disease in patients with acromegaly
Authors: Aleksandra Franczak
Katarzyna Kolačkov
Aleksandra Jawiarczyk-Przybyłowska
Marek Bolanowski
Publication date: 01-02-2018
Publisher: Springer US
Published in: Pituitary / Issue 1/2018
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-017-0840-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Association between FTO gene polymorphisms and HDL cholesterol concentration may cause higher risk of cardiovascular disease in patients with acromegaly

Abstract

Introduction

Materials and methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Treatment of empty sella associated with visual impairment: a systematic review of chiasmapexy techniques

Guidelines versus real life practice: the case of colonoscopy in acromegaly

Bone histomorphometry in acromegaly patients with fragility vertebral fractures

Growth hormone-producing pituitary adenomas in childhood and young adulthood: clinical features and outcomes

Preoperative risk factors for postoperative complications in endoscopic pituitary surgery: a systematic review

Cardiovascular autonomic dysfunction in patients with idiopathic diabetes insipidus

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page